- Home
- WIA vs TRVI Comparison
WIA vs TRVI Comparison
Compare WIA & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WIA
- TRVI
- Stock Information
- Founded
- WIA 2003
- TRVI 2011
- Country
- WIA United States
- TRVI United States
- Employees
- WIA N/A
- TRVI N/A
- Industry
- WIA Trusts Except Educational Religious and Charitable
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- WIA Finance
- TRVI Health Care
- Exchange
- WIA Nasdaq
- TRVI Nasdaq
- Market Cap
- WIA 191.5M
- TRVI 211.4M
- IPO Year
- WIA N/A
- TRVI 2019
- Fundamental
- Price
- WIA $8.06
- TRVI $4.05
- Analyst Decision
- WIA
- TRVI Strong Buy
- Analyst Count
- WIA 0
- TRVI 8
- Target Price
- WIA N/A
- TRVI $9.31
- AVG Volume (30 Days)
- WIA 39.2K
- TRVI 4.2M
- Earning Date
- WIA 01-01-0001
- TRVI 11-06-2024
- Dividend Yield
- WIA 12.29%
- TRVI N/A
- EPS Growth
- WIA N/A
- TRVI N/A
- EPS
- WIA N/A
- TRVI N/A
- Revenue
- WIA N/A
- TRVI N/A
- Revenue This Year
- WIA N/A
- TRVI N/A
- Revenue Next Year
- WIA N/A
- TRVI N/A
- P/E Ratio
- WIA N/A
- TRVI N/A
- Revenue Growth
- WIA N/A
- TRVI N/A
- 52 Week Low
- WIA $7.56
- TRVI $1.27
- 52 Week High
- WIA $8.91
- TRVI $4.68
- Technical
- Relative Strength Index (RSI)
- WIA 27.42
- TRVI 64.87
- Support Level
- WIA $8.09
- TRVI $4.08
- Resistance Level
- WIA $8.31
- TRVI $4.68
- Average True Range (ATR)
- WIA 0.08
- TRVI 0.38
- MACD
- WIA -0.02
- TRVI 0.15
- Stochastic Oscillator
- WIA 11.43
- TRVI 73.00
About WIA Western Asset Inflation-Linked Income Fund
Western Asset Inflation Linked Income Fund is a diversified, closed-end management investment company. The primary investment objective of the group is to provide current income while its secondary investment objective is capital appreciation.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.